Malignant mesothelioma diseases feature an increasing risk due to their severe forms and their association with asbestos exposure. Platinum(II) complexes such as cisplatin and carboplatin are clinically approved for the therapy of mesothelioma often in combination with antimetabolites such as pemetrexed or gemcitabine. It was observed that pathogenic properties of mesothelioma cells and the response of mesothelioma tumors towards platinum-based drugs are strongly influenced by non-coding RNAs, in particular, by small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). These non-coding RNAs controlled drug sensitivity and the development of tumor resistance towards platinum drugs. An overview of the interactions between platinum drugs and non-coding RNAs is given and the influence of non-coding RNAs on platinum drug efficacy in mesothelioma is discussed. Suitable non-coding RNA-modulating agents with potentially beneficial effects on cisplatin treatment of mesothelioma diseases are mentioned. The understanding of mesothelioma diseases concerning the interactions of non-coding RNAs and platinum drugs will optimize existing therapy schemes and pave the way to new treatment options in future.
Keywords: ABC, ATP-binding cassette; AKBA, 3-acetyl-11-keto-β-boswellic acid; AKI, acute kidney injury; Anticancer drugs; Bcl-2, B-cell lymphoma 2; CAF, cancer-associated fibroblast; CBDCA, cyclobutane-1,1-dicarboxylate; Carboplatin; Cisplatin; DADS, diallyl sulfide; DHA, docosahexaenoic acid; DIM, 3,3′-diindolylmethane; DMPM, diffuse malignant peritoneal mesothelioma; EGCG, epigallocatechin-3-gallate; EMT, epithelial-mesenchymal transition; HOTAIR, HOX transcript antisense RNA; I3C, indole-3-carbinol; Long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MPM, malignant pleural mesothelioma; MRP1, multidrug resistance protein 1; Mesothelioma; MicroRNA; NSCLC, non-small cell lung cancer; NaB, sodium butyrate; PDCD4, programmed cell death 4; PEG, polyethylene glycole; PEITC, phenethylisothiocyanate; PTEN, phosphatase and tensin homolog; RA, retinoic acid; SAHA, suberoylanilide hydroxamic acid; SFN, sulforaphane; TNBC, triple-negative breast cancer; TSA, trichostatin A.